Intravitreal Ranibizumab Had Limited Effect on Cystoid Macular Edema Due to Albumin-Bound Paclitaxel: A Case Report and Literature Review

Frontiers in Oncology

Suna Ye²  Shibo Tang²  Jacey Hongjie Ma²  Qiqi Fang³  Jianqiang Xing³  Jinyu Yao³ 

[1] AIER Eye Hospital, Jinan University, Guangzhou, China;AIER Eye Institute, Changsha, China;Retina Department, Hainan AIER Eye Hospital, Haikou, China;

关键词: albumin-bound paclitaxel;    Nab-paclitaxel;    Abraxane;    cystoid macular edema;    ranibizumab;    carbonic anhydrase inhibitor;   

DOI  :  10.3389/fonc.2021.773540

来源: DOAJ

【 摘 要 】

Angiographically silent cystoid macular edema (CME) is a rare complication from nab-paclitaxel. Here we report a 45-year-old woman with breast cancer who developed CME after several months of treatment with albumin-bound paclitaxel (nab-paclitaxel). Her visual acuity did not improve significantly with the cessation of nab-paclitaxel and intravitreal ranibizumab treatment. Then, brinzolamide eye drops were prescribed. One month later, her vision improved, with the macular edema significantly subsided. Finally, we reviewed other cases of CME induced by nab-paclitaxel that have been reported in the literature and discussed the underlying pathogenesis of nab-paclitaxel-induced CME.

【 授权许可】

Unknown